Vincerx Pharma (NASDAQ:VINC) Stock Rating Reaffirmed by Cantor Fitzgerald

Vincerx Pharma (NASDAQ:VINCGet Rating)‘s stock had its “overweight” rating reiterated by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Vincerx Pharma’s FY2022 earnings at ($2.76) EPS and FY2023 earnings at ($2.00) EPS.

A number of other equities analysts also recently weighed in on VINC. B. Riley decreased their target price on shares of Vincerx Pharma from $12.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, June 7th. SVB Leerink decreased their target price on shares of Vincerx Pharma from $6.00 to $5.00 and set an “outperform” rating for the company in a research note on Friday, August 12th. Finally, Chardan Capital decreased their target price on shares of Vincerx Pharma from $11.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, June 7th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $10.20.

Vincerx Pharma Price Performance

Shares of VINC opened at $1.08 on Wednesday. Vincerx Pharma has a one year low of $1.03 and a one year high of $17.49. The company has a 50-day simple moving average of $1.47 and a two-hundred day simple moving average of $2.18. The firm has a market capitalization of $22.89 million, a PE ratio of -0.32 and a beta of 1.28.

Vincerx Pharma (NASDAQ:VINCGet Rating) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.04. Analysts expect that Vincerx Pharma will post -2.65 EPS for the current fiscal year.

Insider Activity at Vincerx Pharma

In other news, Director Christopher P. Lowe purchased 18,400 shares of Vincerx Pharma stock in a transaction that occurred on Wednesday, August 24th. The stock was bought at an average price of $1.65 per share, with a total value of $30,360.00. Following the completion of the transaction, the director now directly owns 28,400 shares of the company’s stock, valued at $46,860. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, insider Raquel E. Izumi purchased 40,000 shares of Vincerx Pharma stock in a transaction that occurred on Monday, June 27th. The stock was bought at an average price of $1.41 per share, with a total value of $56,400.00. Following the completion of the transaction, the insider now directly owns 40,000 shares of the company’s stock, valued at $56,400. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Christopher P. Lowe bought 18,400 shares of the business’s stock in a transaction on Wednesday, August 24th. The stock was bought at an average cost of $1.65 per share, with a total value of $30,360.00. Following the transaction, the director now owns 28,400 shares in the company, valued at approximately $46,860. The disclosure for this purchase can be found here. 23.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Vincerx Pharma

A number of large investors have recently added to or reduced their stakes in VINC. Goldman Sachs Group Inc. grew its position in Vincerx Pharma by 21.3% in the 2nd quarter. Goldman Sachs Group Inc. now owns 36,126 shares of the company’s stock worth $48,000 after purchasing an additional 6,334 shares during the period. Rhumbline Advisers bought a new stake in Vincerx Pharma in the 1st quarter worth approximately $53,000. ExodusPoint Capital Management LP bought a new stake in Vincerx Pharma in the 2nd quarter worth approximately $132,000. Bank of Montreal Can bought a new stake in Vincerx Pharma in the 1st quarter worth approximately $332,000. Finally, Millennium Management LLC grew its position in Vincerx Pharma by 562.4% in the 2nd quarter. Millennium Management LLC now owns 306,598 shares of the company’s stock worth $405,000 after purchasing an additional 260,310 shares during the period. Institutional investors own 65.91% of the company’s stock.

Vincerx Pharma Company Profile

(Get Rating)

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies.

Featured Stories

Analyst Recommendations for Vincerx Pharma (NASDAQ:VINC)

Receive News & Ratings for Vincerx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vincerx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.